GPP
ACAD icon

Great Point Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Great Point Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-311,217
Closed -$8.03M – 31
2021
Q1 		$8.03M Sell
311,217
-409,285
-57% -$18M 1.66% 21
2020
Q4 		$38.5M Sell
720,502
-1,201,061
-63% -$59.6M 6.26% 4
2020
Q3 		$79.3M Buy
1,921,563
+116,570
+6% +$5.03M 7.13% 3
2020
Q2 		$87.5M Sell
1,804,993
-190,754
-10% -$9.16M 6.99% 4
2020
Q1 		$84.3M Buy
1,995,747
+745,747
+60% +$30.7M 8.81% 1
2019
Q4 		$53.5M Sell
1,250,000
-940,742
-43% -$40.9M 4.66% 10
2019
Q3 		$78.8M Buy
2,190,742
+690,742
+46% +$20.9M 7.24% 3
2019
Q2 		$40.1M Sell
1,500,000
-500,000
-25% -$12.8M 4.45% 9
2019
Q1 		$53.7M Sell
2,000,000
-752,256
-27% -$17.6M 5.32% 5
2018
Q4 		$44.5M Buy
2,752,256
+1,556,158
+130% +$30.2M 5.63% 5
2018
Q3 		$24.8M Sell
1,196,098
-803,902
-40% -$12.6M 3.87% 13
2018
Q2 		$30.5M Buy
+2,000,000
New +$35.7M 4.23% 9
2017
Q1 		– Sell
-270,000
Closed -$7.79M – 38
2016
Q4 		$7.79M Buy
+270,000
New +$7.14M 1.6% 20
2016
Q2 		– Sell
-100,000
Closed -$2.8M – 40
2016
Q1 		$2.8M Buy
+100,000
New +$2.18M 1% 25

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Great Point Partners's ACAD Position: Q2 2021 in Review

Great Point Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 311,217 shares — an estimated $8.03M sold.

Great Point Partners first reported a position in ACAD in Q1 2016 and held it in 14 quarters. The position peaked at $87.5M in Q2 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • Great Point Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Great Point Partners sold 311,217 Acadia Pharmaceuticals shares in Q2 2021, an estimated $8.03M.
  • Great Point Partners first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 14 quarters.
  • Great Point Partners's Acadia Pharmaceuticals position peaked at $87.5M in Q2 2020.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Great Point Partners's 13F filing for Q2 2021, filed 16 Aug 2021.